List view / Grid view
A specialised group of immune cells in the gut has been found to prevent allergic reactions - a discovery that could lead to new treatments for allergies and autoimmune diseases.
Researchers have revealed that genetically enhanced expression of GSDMB causes a disturbed interferon-response.
The new findings could lead to a therapeutic target for immune-related disorders, like multiple sclerosis.
US researchers have connected a rare T cell called Th9 with treating allergies, testing in mouse models with asthma.
US research about immunological memory may help development of potential vaccines or immunotherapies for cancer and various inflammatory diseases.
US researchers uncover how to make asthma and COPD medication more potent, which could also improve how long they work in patients who need frequent doses.
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
In this article, Dr Jon Volmer and Dr Jon Lenn discuss a new approach to formulation models to test drug delivery based on reconstituted nasal epithelium.
A new conjugate vaccine has shown promise at protecting mice against the effects of cytokines associated with asthma.
Researchers have discovered that giving L-tyrosine and PCS to mice prevents lung inflammation and an allergic asthma response.
Scientists have developed an inhaled treatment for asthma that prevents excess mucus from building up in mice.
Study identifies a promising new compound that can open constricted airways and could be a promising treatment for obstructive lung diseases.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
According to researchers, the DMBT1S8 molecule can halt inflammation in the respiratory tract through its interaction with the Siglec-8 receptor on immune cells.
